France-based Sanofi Pasteur has signed an agreement with AstraZeneca’s global biologics research and development arm MedImmune to develop and commercialise a monoclonal antibody known as MEDI8897.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MEDI8897 prevents respiratory syncytial virus (RSV) associated illness in newborns and infants.

Under the agreement, Sanofi Pasteur will make an upfront payment of €120m and up to €495m upon achievement of certain development and sales-related milestones.

Sanofi Pasteur head David Loew said: "As a global leader in the pediatric vaccine industry, this deal with MedImmune therefore makes perfect sense for Sanofi Pasteur.

See Also:

“RSV causes major, seasonal worldwide outbreaks and the severity is predominant among young infants."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The monoclonal antibody (mAb) MEDI8897 neutralises RSV by binding the RSV fusion (F) protein expressed on virions and infected cells and is being developed for the passive immunisation of the infant population.

It has been engineered to have a long half-life to enable the requirement of only one dose for the entire RSV season.

"RSV causes major, seasonal worldwide outbreaks and the severity is predominant among young infants."

At present, MEDI8897 is being investigated in a Phase IIb study in pre-term infants, with further plans for a Phase III trial in healthy full-term infants.

The US FDA granted fast-track designation to MEDI8897 in 2015.

All development activity up to the first approval will be led by MedImmune, while AstraZeneca will retain MEDI8897 manufacturing activities.

Sanofi-Pasteur will lead the commercialisation activities for the antibody.

Image: This electron micrograph depicts the Respiratory Syncytial Virus (RSV) pathogen. Photo: courtesy of CDC / Dr Erskine Palmer.